<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01804387</url>
  </required_header>
  <id_info>
    <org_study_id>TeSLA study</org_study_id>
    <nct_id>NCT01804387</nct_id>
  </id_info>
  <brief_title>Comparison of Telbivudine Plus Adefovir With Lamivudine Plus Adefovir for the Treatment of Lamivudine-resistant Chronic Hepatitis B at 52 Weeks: A Pilot Study</brief_title>
  <acronym>TeSLA</acronym>
  <official_title>Comparison of Telbivudine Plus Adefovir With Lamivudine Plus Adefovir for the Treatment of Lamivudine-resistant Chronic Hepatitis B at 52 Weeks: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Korea University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lamivudine had been widely used for treatment-naïve chronic hepatitis B patients. However,
      development of antiviral resistance has been known as the major drawback: Incidence of
      lamivudine resistance was reported to be approximately 70% after 5 years (Lok AS et al,
      2003). For the treatment of lamivudine resistance, adefovir has been widely used (Lok AS and
      McMahon B, 2009). However, switching to adefovir monotherapy was also reported to be at high
      risk of resistance, 25% at year 2 (Yeon JE et al, 2006). Recently, adding adefovir on
      lamivudine was shown to be superior to switching to adefovir monotherapy by decreasing the
      adefovir resistance (Rapti I et al, 2007, Lampertico P et al, 2007). However, combination of
      adefovir and lamivudine does not increase antiviral activity compared with adefovir
      monotherapy in patients with lamivudine resistance (Peters MG et al, 2004). As many patients
      are still viremic with the treatment of lamivudine and adefovir over 1 year, the
      investigators need more potent combination of the drugs. Telbivudine is a new nucleoside
      analogue with potent antiviral activity. The previous phase III study has shown the
      superiority of telbivudine over lamivudine in HBeAg positive and negative subjects (Lai CL et
      al, 2007). Therefore, telbivudine plus adefovir may be a better treatment option than
      lamivudine plus adefovir for the lamivudine-resistant chronic hepatitis B patients. No study
      assessing the efficacy of telbivudine plus adefovir has been conducted for these patients.
      The aim of this study is to evaluate the safety and efficacy of telbivudine plus adefovir
      compared with lamivudine plus adefovir in lamivudine resistant chronic hepatitis B patients
      at the end of 1 year follow-up,
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2011</start_date>
  <completion_date type="Anticipated">May 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The mean reduction of serum HBV DNA from the baseline at week 52.</measure>
    <time_frame>up to the end of year 1 (52 weeks)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>HBV DNA undetectability(&lt;20 IU/mL)</measure>
    <time_frame>up to the end of year 1 (52 weeks)</time_frame>
    <description>At the end of year 1 in the two groups, HBV DNA undetectability by real time PCR will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean serum HBV DNA level</measure>
    <time_frame>up to the end of year 1 (52 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of ALT normalization</measure>
    <time_frame>up to the end of year 1 (52 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rates of HBeAg loss</measure>
    <time_frame>up to the end of year 1 (52 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of HBeAg seroconversion at week 52.</measure>
    <time_frame>up to the end of year 1 (52 weeks)</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Antiviral resistance rate</measure>
    <time_frame>up to the end of year 1 (52 weeks)</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Telbivudine plus adefovir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>study drugs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lamivudine plus adefovir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>standard drugs</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>telbivudine plus adefovir</intervention_name>
    <description>telbivudine 600 mg qd plus adefovir 10 mg qd</description>
    <arm_group_label>Telbivudine plus adefovir</arm_group_label>
    <other_name>telbivudine (sevibo)</other_name>
    <other_name>adefovir (hepsera)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lamivudine plus adefovir</intervention_name>
    <description>lamivudine 100 mg qd plus adefovir 10mg qd</description>
    <arm_group_label>Lamivudine plus adefovir</arm_group_label>
    <other_name>lamivudine (zeffix)</other_name>
    <other_name>adefovir (hepsera)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. HBeAg positive or negative chronic hepatitis B patients (positive HBsAg more than 6
             months)

          2. Age ≥ 18 years old, and ≤70 years old

          3. Previous treatment with lamivudine more than 6 months

          4. Being on lamivudine at the time of screening

          5. Confirmed genotypic resistance to lamivudine by RFMP (rtM204V or I)

          6. Presence of virologic breakthrough ≥1 log increase of HBV DNA above na dir)

          7. HBV DNA ≥ 20,000 IU/mL

          8. Patient willing to give an informed consent (If patient is &lt;20 years old, the parent
             or legal guardian also need to give an informed consent)

        Exclusion Criteria:

          1. Out of inclusion criteria

          2. Presence of adefovir resistance (rtA181T or V, rtN236T) by RFMP assay

          3. Laboratory abnormalities as follows at screening: AFP&gt;100 ng/mL, serum phosphorous
             level&lt;2.4 mg/dL, serum creatinine level&gt; 1.5 mg/dL or creatinine clearance &lt; 50 mL/min

          4. Patient with a history of decompensated liver disease: Any patients with a history of
             ascites, hepatic encephalopathy, variceal bleeding, jaundice, or CTP&gt;7 points should
             be excluded.

          5. History of treatment with nucleos(t)ide analogues other than lamivudine more than 4
             weeks

          6. History of immune modulatory drugs (interferon, thymosin-alfa) within 24 weeks of
             screening

          7. Liver transplant patient

          8. Patient co-infected with HIV, HCV, or HDV

          9. Patient with metabolic or genetic liver disease that may affect serum ALT level

         10. Habitual alcohol consumption (&gt;140 g/week for male, &gt;70 g/week for female)

         11. Patient not able to stop drugs that may affect ALT or HBV DNA level during study
             periods (ie. Steroid, immune-suppressants, non-steroidal anti-inflammatory drugs,
             acetaminophen,)

         12. Pregnant or lactating woman

         13. Menstruating woman unwilling to use appropriate methods of contraception (ie. Condom,
             oral contraceptives, tubal ligation)

         14. Patient with hepatocellular carcinoma (treated or not treated)

         15. Patient with any untreated malignancy

         16. Patient with history of malignancy cured within 5 years of screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyung Joon Yim, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hyung Joon Yim, M.D</last_name>
    <phone>82-31-412-5583</phone>
    <email>gudwns21@medimail.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Korea University Ansan Hospital</name>
      <address>
        <city>Ansan</city>
        <state>Gyeonggi-do</state>
        <zip>425-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyung Joon Yim, M.D</last_name>
      <phone>82-31-412-5583</phone>
      <email>gudwns21@medimail.co.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 23, 2011</study_first_submitted>
  <study_first_submitted_qc>March 3, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2013</study_first_posted>
  <last_update_submitted>March 3, 2013</last_update_submitted>
  <last_update_submitted_qc>March 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Korea University</investigator_affiliation>
    <investigator_full_name>Hyung Joon Yim</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <keyword>Chronic Hepatitis B</keyword>
  <keyword>Telbivudine</keyword>
  <keyword>Adefovir</keyword>
  <keyword>Lamivudine resistance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Adefovir</mesh_term>
    <mesh_term>Adefovir dipivoxil</mesh_term>
    <mesh_term>Telbivudine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

